Adebrelimab

Summary

Adebrelimab (CHEMBL4297828) is a phase-3 clinical-stage antibody; indicated across 22 conditions including small cell lung carcinoma and squamous cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 22 conditions
• Clinical trials: 188

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297828
Name	Adebrelimab
Type	Antibody
Max phase	3

Also known as: Adebrelimab, HTI-1088, Shr-1316, SHR-1316, ADEBRELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

22 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
squamous cell carcinoma	2	MONDO:0005096	EFO:0000707
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
breast neoplasm	2	MONDO:0021100	MONDO:0007254
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
ovarian neoplasm	2	MONDO:0021068	EFO:0003893
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
oral cavity squamous cell carcinoma	2	MONDO:0004958	EFO:0000199
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
rectal cancer	2	MONDO:0006519	EFO:1000657
intrahepatic cholangiocarcinoma	2	MONDO:0003210	EFO:1001961
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
adenocarcinoma	2	MONDO:0004970	MONDO:0003219
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
neoplasm	1	MONDO:0005070	EFO:0000616
colorectal neoplasm	1	MONDO:0005335	MONDO:0005575

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 188.

Phase distribution

Phase	Trials
PHASE2	124
PHASE1/PHASE2	26
PHASE1	16
PHASE3	10
Not specified	8
EARLY_PHASE1	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04516681	PHASE3	RECRUITING	Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
NCT06335355	PHASE2/PHASE3	NOT_YET_RECRUITING	A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
NCT06618664	PHASE3	RECRUITING	A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
NCT06672133	PHASE3	NOT_YET_RECRUITING	Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC
NCT07111832	PHASE3	RECRUITING	A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
NCT07168200	PHASE3	RECRUITING	A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
NCT07229625	PHASE3	RECRUITING	A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
NCT07238569	PHASE3	NOT_YET_RECRUITING	Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
NCT07393542	PHASE3	RECRUITING	A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
NCT07560358	PHASE3	NOT_YET_RECRUITING	Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
NCT03711305	PHASE3	UNKNOWN	Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
NCT04303988	PHASE2	RECRUITING	A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
NCT05076682	PHASE2	RECRUITING	Reverse Triple Negative Immune Resistant Breast Cancer
NCT05205200	PHASE2	RECRUITING	Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02
NCT05444088	PHASE1/PHASE2	RECRUITING	Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
NCT05582499	PHASE2	RECRUITING	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
NCT05671822	PHASE2	RECRUITING	Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
NCT05753826	PHASE2	RECRUITING	Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
NCT05924997	PHASE1/PHASE2	RECRUITING	Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT05975463	PHASE2	NOT_YET_RECRUITING	Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy
NCT06091124	PHASE2	RECRUITING	Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06149130	PHASE2	RECRUITING	Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
NCT06149767	PHASE2	NOT_YET_RECRUITING	Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
NCT06177522	PHASE2	NOT_YET_RECRUITING	Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177925	PHASE2	RECRUITING	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
NCT06178211	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
NCT06199271	PHASE2	NOT_YET_RECRUITING	Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma
NCT06208462	PHASE2	RECRUITING	Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
NCT06222879	PHASE1/PHASE2	RECRUITING	Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
NCT06229067	PHASE2	NOT_YET_RECRUITING	Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
NCT06234007	PHASE2	RECRUITING	Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
NCT06236997	PHASE2	NOT_YET_RECRUITING	Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06261125	PHASE2	RECRUITING	Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
NCT06266832	PHASE2	RECRUITING	The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
NCT06277791	PHASE2	RECRUITING	The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
NCT06280508	PHASE2	RECRUITING	Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
NCT06282445	PHASE2	RECRUITING	Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
NCT06296563	PHASE2	RECRUITING	Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
NCT06298968	PHASE2	RECRUITING	Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma
NCT06299371	PHASE2	NOT_YET_RECRUITING	Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).